Astellas Pharma promoted David Musselman to area VP of sales for primary care and specialty for the East Coast, and it also named Lynn Gerber to the same role for the West Coast.
Musselman and Gerber each lead a team of five sales directors, who are part of Astellas’ 370-member primary care and specialty teams.
Musselman is based in Charleston, South Carolina, and Gerber is based in Chicago, Illinois. They report to Steve Sabus, VP of sales, primary care/specialty and hospital, who is in Chicago.
“With the changing healthcare landscape, we aim to provide development opportunities and appropriate training so that our teams continue to grow,” said Musselman. “It could be new skillsets, in terms of understanding what the marketplace looks like, and understanding from a knowledge standpoint to make sure they are as clinically sharp as they can be.”
Some of Astellas’ key products include overactive bladder therapy VESIcare, immunosuppressive drug Prograf, and its top-selling therapy, prostate cancer drug Xtandi. Xtandi generated about $252 billion in global sales in 2016, consistent with the previous year, but its U.S. sales fell in 2016, to $131 billion in 2016 compared to $148 billion in 2015.
Musselman was most recently director of regional accounts for the East Coast, a role that put him in charge of the drugmaker’s oncology, urology, transplant, and antifungal brands. He takes over Gerber’s previous role as she transitions to the West Coast position. The drugmaker declined to say who Gerber is replacing.
Astellas also announced two other promotions in June: it named Caroline Walkinshaw, most recently senior director of global market intelligence and commercial analysis, the executive director of market intelligence and analytics for marketing strategy, and Jacquelyn Bonnell, previously the head of key oncology accounts in the Western region, to national VP of oncology sales for the U.S. commercial organization.